ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Teva Pharmaceutical Industries's annualizedNet Income for the quarter that ended in Mar. 2026 was R$7,719 Mil.
Teva Pharmaceutical Industries's average Total Assets over the quarter that ended in Mar. 2026 was R$215,851 Mil. Therefore, Teva Pharmaceutical Industries's annualized ROA % for the quarter that ended in Mar. 2026 was 3.58%.
The historical rank and industry rank for Teva Pharmaceutical Industries's ROA % or its related term are showing as below:
BSP:T1EV34'
s ROA % Range Over the Past 10 Years
Min: -19.88 Med: -2.48 Max: 3.93
Current: 3.93
During the past 13 years, Teva Pharmaceutical Industries's highest ROA % was 3.93%. The lowest was -19.88%. And the median was -2.48%.
BSP:T1EV34's ROA % is ranked better than 56.08% of 1004
companies
in the Drug Manufacturers industry
Industry Median: 2.75
vs BSP:T1EV34: 3.93
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Teva Pharmaceutical Industries ROA % Related Terms
Teva Pharmaceutical Industries ROA % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Teva Pharmaceutical Industries ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's ROA % distribution charts can be found below:
* The bar in red indicates where Teva Pharmaceutical Industries's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Teva Pharmaceutical Industries (BSP:T1EV34) has a ROA % of 3.58% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Teva Pharmaceutical Industries and its competitors. According to the industry distribution chart, Teva Pharmaceutical Industries ranks #441 out of 1004 companies in the Drug Manufacturers industry, placing it in the top 43.9%.
Is Teva Pharmaceutical Industries' ROA % too high?
Teva Pharmaceutical Industries' current ROA % is 3.58%. The Drug Manufacturers industry median ROA % is 2.75. Teva Pharmaceutical Industries' value of 3.58% is 30.2% above this industry median. Based on the distribution chart, Teva Pharmaceutical Industries ranks #441 out of 1004 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Teva Pharmaceutical Industries has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Teva Pharmaceutical Industries' ROA % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Teva Pharmaceutical Industries ranks #441 out of 1004 companies for ROA %. This puts Teva Pharmaceutical Industries in the upper half of its industry. The industry median ROA % is 2.75. Teva Pharmaceutical Industries' value of 3.58% is 30.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.75, based on 1,004 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Teva Pharmaceutical Industries's current ROA % of 3.58% is 30.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Teva Pharmaceutical Industries and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Teva Pharmaceutical Industries's current ROA % is 3.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teva Pharmaceutical Industries stock overvalued right now?
Teva Pharmaceutical Industries (BSP:T1EV34) has a current ROA % of 3.58%. The stock's GF Value™ is R$53.85, compared to a current price of R$85.99 — trading 59.7% above its estimated fair value. The current ROA % is 3.58% and 30.2% above the Drug Manufacturers industry median of 2.75. Teva Pharmaceutical Industries' overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Teva Pharmaceutical Industries (BSP:T1EV34), the current ROA % is 3.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Teva Pharmaceutical Industries (BSP:T1EV34) Overvalued in 2026?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued.
The current stock price of R$85.99 is trading 59.7% above its estimated GF Value™ of R$53.85.
Key valuation signals for BSP:T1EV34:
ROA %: 3.58%
GF Value™: R$53.85 vs. price of R$85.99 (59.7% above fair value)
Industry Position: 30.2% above the Drug Manufacturers median (#441 of 1004)
No single metric tells the full story. See the BSP:T1EV34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Teva Pharmaceutical Industries Business Description
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
60GF Score
Get the complete analysis for BSP:T1EV34
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:T1EV34 has been successfully added to your 
